
MRD-Guided Triplet Therapy Leads to Deep Remissions in R/R CLL
The triple combination therapy of venetoclax, zanubrutinib, and obinutuzumab, guided by measurable residual disease (MRD), showed promise in relapsed or refractory chronic lymphocytic leukemia (R/R CLL), a new report found.1 The study was published in …